RNA nanomedicines: the next generation drugs?

Peer, 2014, Harnessing RNAi nanomedicine for precision therapy, Mol Cell Therap, 2, 5, 10.1186/2052-8426-2-5 Haussecker, 2014, Current issues of RNAi therapeutics delivery and development, J Control Release, 195, 49, 10.1016/j.jconrel.2014.07.056 Ozcan, 2015, Preclinical and clinical development of siRNA-based therapeutics, Adv Drug Deliv Rev, 10.1016/j.addr.2015.01.007 Daka, 2012, RNAi-based nanomedicines for targeted personalized therapy, Adv Drug Deliv Rev, 64, 1508, 10.1016/j.addr.2012.08.014 Pecot, 2011, RNA interference in the clinic: challenges and future directions, Nat Rev Cancer, 11, 59, 10.1038/nrc2966 Meade, 2014, Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications, Nat Biotechnol, 32, 1256, 10.1038/nbt.3078 Wu, 2014, 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity, Nat Commun, 5, 3459, 10.1038/ncomms4459 Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat Nanotechnol, 2, 751, 10.1038/nnano.2007.387 Dahlman, 2014, In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight, Nat Nanotechnol, 9, 648, 10.1038/nnano.2014.84 Sun, 2015, Targeted therapy for breast cancer stem cells by liposomal delivery of siRNA against fibronectin EDB, Adv Healthc Mater, 4, 1675, 10.1002/adhm.201500190 Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387 Cohen, 2014, Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters, ACS Nano, 8, 2183, 10.1021/nn500205b Wu, 2015, Aptamers: active targeting ligands for cancer diagnosis and therapy, Theranostics, 5, 322, 10.7150/thno.10257 Wong, 2012, Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo, Nucleic Acid Therap, 22, 380, 10.1089/nat.2012.0389 Landesman-Milo, 2015, Nanomedicine as an emerging platform for metastatic lung cancer therapy, Cancer Metastasis Rev, 34, 291, 10.1007/s10555-015-9554-4 Cohen, 2015, Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles, ACS Nano, 9, 1581, 10.1021/nn506248s Ramishetti, 2015, Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles, ACS Nano, 10.1021/acsnano.5b02796 Kedmi, 2010, The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation, Biomaterials, 31, 6867, 10.1016/j.biomaterials.2010.05.027 Landesman-Milo, 2014, Toxicity profiling of several common RNAi-based nanomedicines: a comparative study, Drug Deliv Transl Res, 4, 96, 10.1007/s13346-013-0158-7 Mizrahy, 2014, Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles, Nanoscale, 6, 3742, 10.1039/C3NR06102G Sahay, 2010, Endocytosis of nanomedicines, J Control Release, 145, 182, 10.1016/j.jconrel.2010.01.036 Boussif, 1995, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine, Proc Natl Acad Sci U S A, 92, 7297, 10.1073/pnas.92.16.7297 Sahay, 2013, Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling, Nat Biotechnol, 31, 653, 10.1038/nbt.2614 Khan, 2009, Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs, Nat Biotechnol, 27, 549, 10.1038/nbt.1543 Fellmann, 2014, Stable RNA interference rules for silencing, Nat Cell Biol, 16, 10, 10.1038/ncb2895 Cuccato, 2011, Modeling RNA interference in mammalian cells, BMC Syst Biol, 5, 19, 10.1186/1752-0509-5-19 Mikhail, 2014, Image-based analysis of the size- and time-dependent penetration of polymeric micelles in multicellular tumor spheroids and tumor xenografts, Int J Pharm, 464, 168, 10.1016/j.ijpharm.2014.01.010 Minchinton, 2006, Drug penetration in solid tumours, Nat Rev Cancer, 6, 583, 10.1038/nrc1893 Nichols, 2014, EPR: evidence fallacy, J Control Release, 190, 451, 10.1016/j.jconrel.2014.03.057 Jain, 2010, Delivering nanomedicine to solid tumors, Nat Rev Clin Oncol, 7, 653, 10.1038/nrclinonc.2010.139 Wang, 2011, Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming, Nanomedicine (Lond), 6, 1605, 10.2217/nnm.11.141 Sano, 2013, Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors, ACS Nano, 7, 717, 10.1021/nn305011p Lu, 2007, Tumor priming enhances delivery and efficacy of nanomedicines, J Pharmacol Exp Therap, 322, 80, 10.1124/jpet.107.121632 Khawar, 2015, Improving drug delivery to solid tumors: priming the tumor microenvironment, J Control Release, 201, 78, 10.1016/j.jconrel.2014.12.018 Philip, 2013, HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression, Carcinogenesis, 34, 1699, 10.1093/carcin/bgt209 Albini, 2015, Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity, Connect Tissue Res, 1 Yu, 2014, Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling, Br J Cancer, 110, 724, 10.1038/bjc.2013.768 Jung, 2013, Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis, Nat Commun, 4, 1795, 10.1038/ncomms2766 Plaks, 2015, The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?, Cell Stem Cell, 16, 225, 10.1016/j.stem.2015.02.015 Pickup, 2013, The roles of TGFbeta in the tumour microenvironment, Nat Rev Cancer, 13, 788, 10.1038/nrc3603 Tabassum, 2015, Tumorigenesis: it takes a village, Nat Rev Cancer, 15, 473, 10.1038/nrc3971 Zins, 2015, Modulating the tumor microenvironment with RNA interference as a cancer treatment strategy, Methods Mol Biol, 1218, 143, 10.1007/978-1-4939-1538-5_9 Quail, 2013, Microenvironmental regulation of tumor progression and metastasis, Nat Med, 19, 1423, 10.1038/nm.3394 Cai, 2013, Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model, BMB Rep, 46, 252, 10.5483/BMBRep.2013.46.5.172 Conde, 2015, Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells, Adv Funct Mater, 25, 4183, 10.1002/adfm.201501283 Xu, 2014, Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment, ACS Nano, 8, 3636, 10.1021/nn500216y Cheng, 2015, MicroRNA silencing for cancer therapy targeted to the tumour microenvironment, Nature, 518, 107, 10.1038/nature13905 Liu, 2015, Delivery of siRNA using CXCR4-targeted nanoparticles modulates tumor microenvironment and achieves a potent anti-tumor response in liver cancer, Mol Therap Parvani, 2015, Silencing beta3 integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer, Cancer Res, 75, 2316, 10.1158/0008-5472.CAN-14-3485 Conley, 2012, Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia, Proc Natl Acad Sci U S A, 109, 2784, 10.1073/pnas.1018866109 Kerbel, 2008, Tumor angiogenesis, N Engl J Med, 358, 2039, 10.1056/NEJMra0706596 Luo, 2015, Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo, Biomaterials, 38, 50, 10.1016/j.biomaterials.2014.10.050 Herrmann, 2014, CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells, J Clin Invest, 124, 2977, 10.1172/JCI73174 Bobrie, 2012, Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression, Cancer Res, 72, 4920, 10.1158/0008-5472.CAN-12-0925 Peer, 2008, Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target, Science, 319, 627, 10.1126/science.1149859 Peer, 2007, Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1, Proc Natl Acad Sci U S A, 104, 4095, 10.1073/pnas.0608491104 Wittrup, 2015, Knocking down disease: a progress report on siRNA therapeutics, Nat Rev Genet, 16, 543, 10.1038/nrg3978 Conde, 2015, Are RNAi and miRNA therapeutics truly dead?, Trends Biotechnol, 33, 141, 10.1016/j.tibtech.2014.12.005 Janssen, 2013, Treatment of HCV infection by targeting microRNA, N Engl J Med, 368, 1685, 10.1056/NEJMoa1209026 Coelho, 2013, Safety and efficacy of RNAi therapy for transthyretin amyloidosis, N Engl J Med, 369, 819, 10.1056/NEJMoa1208760 Martinez, 2014, In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma, Mol Therap, 22, 81, 10.1038/mt.2013.216